27th May 2022 08:59
(Alliance News) - GSK PLC on Friday said China's National Medical Products Administration has approved the use of its HPV vaccine Cervarix for girls aged 9 to 14.
The pharmaceutical firm said that the two-dose vaccine prevents certain types of cancer-causing human papillomavirus. Notably, cervical cancer, cervical intraepithelial neoplasia and adenocarcinoma in situ.
GSK added that in 2020, there were approximately 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China.
The authorisation of the vaccine by the Chinese regulators adds China to a list of around 100 countries who have approved its use.
The three-dose vaccine remains in place for girls and women aged 15-45 in China.
Shares in GSK were down 0.4% at 1,746.60 pence each in London on Friday morning.
By Sophie Rose; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline